RT Journal Article
SR Electronic
T1 Whole-genome DNA methylation profiling of CD14+ monocytes reveals disease status and activity differences in Crohn’s disease patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.09.20033043
DO 10.1101/2020.03.09.20033043
A1 Andrew Y.F. Li Yim
A1 Nicolette W. Duijvis
A1 Mohammed Ghiboub
A1 Catriona Sharp
A1 Enrico Ferrero
A1 Marcel M.A.M. Mannens
A1 Geert R. D’Haens
A1 Wouter J. de Jonge
A1 Anje A. te Velde
A1 Peter Henneman
YR 2020
UL http://medrxiv.org/content/early/2020/03/12/2020.03.09.20033043.abstract
AB Crohn’s disease (CD) is a multifactorial incurable chronic disorder. Current medical treatment seeks to induce and maintain a state of remission. During episodes of inflammation, monocytes infiltrate inflamed mucosa whereupon they differentiate into macrophages with a pro-inflammatory phenotype. Here, we sought to characterize the circulating monocytes by profiling their DNA methylome and relate it to the level of CD activity. We gathered an all-female age-matched cohort of 16 CD patients and 7 non-CD volunteers. CD patients were further subdivided into 8 CD patients with active disease (CD-active) and 8 CD patients in remission (CD-remissive) as determined by physician global assessment. We identified 15 and 12 differentially methylated genes (DMGs) when comparing CD with non-CD and CD-active with CD-remissive, respectively. Differential methylation was predominantly found in the promoter regions of inflammatory genes. Comparing our observations with gene expression data on classical (CD14++CD16-), non-classical (CD14+CD16++) and intermediate (CD14++CD16+) monocytes indicated that while 7 DMGs were differentially expressed across the 3 subsets, the remaining DMGs could not immediately be associated with differences in known populations. We conclude that CD activity is associated with differences in DNA methylation at the promoter region of inflammation-associated genes.Competing Interest StatementA.Y.F.L.Y., C.S. and E.F. were employed at GlaxoSmithKline. E.F. was employed at Novartis. GlaxoSmithKline and Novartis had no additional role in the study design, data collection, decision to publish or the preparation of the manuscript. W.J.J. was financially supported by GlaxoSmithKline, Maed Johnsson and Schwabe. None of the aforementioned funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.Funding StatementM.G. and A.Y.F.L.Y. were funded by European Union’s Horizon 2020 research and innovation program under Grant Agreement No. ITN-2014-EID-641665.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe DNA methylation generated in this study has been published under controlled access for research purposes at the European Genome-phenome Archive at EGAD00010001846. All bash and R scripts have been made available on GitHub and can be found at https://github.com/ND91/PRJ0000002_CDMON. https://github.com/ND91/PRJ0000002_CDMON https://ega-archive.org/datasets/EGAD00010001846